



Financial Tear Sheet

Corporate Profile

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland.


Primary IR Contact

Nichol Ochsner
Executive Director, Investor Relations & Corporate Communications
Phone: 732-754-2545
E-mail: nochsner@aralez.com

Stock Performance

ARLZ (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.41
Change (%)	0.00 (0.00%)
Volume	100
52 Week Low	\$0.95
Market Cap	\$94,308,936
Rolling EPS	-1.68
PE Ratio	0
Shares Outstanding	66,885,770

Data as of 12/14/17 4:00 p.m. ET



Recent Headlines & Events

11/30/17
[Aralez Announces Departure of Chief Financial Officer](#)

11/09/17
[Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter](#)

10/25/17
[Aralez To Report Third Quarter 2017 Financial Results On November 9, 2017](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/12/17	4
12/07/17	8-K
12/04/17	4
12/04/17	3

Corporate Governance

[Neal F. Fowler](#)

[Arthur S. Kirsch](#)

[Kenneth B. Lee, Jr.](#)

[Seth A. Rudnick, M.D.](#)

[F. Martin Thrasher](#)

[Adrian Adams](#)

[Rob Harris](#)

Data provided by Nasdaq. Minimum 15 minutes delayed.